US demand for vaccines will grow 8.6 percent annually through 2008 as the first products for AIDS, cancer, genital herpes and West Nile virus enter the market. Pediatric and hepatitis preparations will remain dominant while influenza and travel vaccines grow the fastest among presently available human products.
This study analyzes the $4.9 billion US vaccines industry. It presents historical (1993, 1998, 2003) demand data and forecasts to 2008 and 2013 by type (e.g., pediatric, hepatitis, biodefense, smallpox, anthrax, influenza, Encephalitis, rabies, SARS, meningococcal, BCG, livestock, companion animal).
The study also presents macro- and socioeconomic demand indicator data, details industry structure and market share, and profiles 25 leading industry competitors including Aventis Pasteur, Wyeth, Medimmune, Merck, GlaxoSmithKline, Chiron, Pfizer, Merial, Intervet, Acambis, and VaxGen.